Lobe Sciences said it has entered into a commercial distribution agreement with Pentec Health for Altemia, a medical food with Lobe’s proprietary formulation of emulsified docosahexaenoic acid ethyl ester (DHA) concentration designed for patients with sickle cell disease (SCD).
Through the agreement, clinical nutrition and specialty care services provider Pentec will hold exclusive rights to distribute Altemia in the United States and US territories.
It is expected Altemia will be available to patients with SCD throughout the US by the second half of 2023.
Lobe said that this distribution agreement was the company’s first step in the global launch of Altemia. It is the first medical food in the US designed specifically to support patients with SCD, the company noted.
“We are pleased to be working with Pentec Health to provide Altemia to this underserved but significant unmet patient need in children and adults suffering from SCD,” said Lobe CEO Philip Young.
“Leveraging its previous success managing distribution and payer interactions in the Medical Food market, working with Pentec Health will ensure a smooth launch of Altemia.”
Pentec CEO Matthew Deans added in a statement: “In our mission to solve complex care challenges, the partnership with Lobe, to both distribute and provide patient support services for Altemia, strengthens our clinical nutrition platform and bolsters our medical food offering."
Lobe is a pharmaceutical company focused on developing transformative medicines to treat orphan diseases.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie